Business Description
Silence Therapeutics PLC
ISIN : US82686Q1013
Share Class Description:
SLN: ADRDescription
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 198.24 | |||||
| Equity-to-Asset | 0.18 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 1.75 | |||||
| Beneish M-Score | -2.42 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 47.5 | |||||
| 3-Year EBITDA Growth Rate | 1 | |||||
| 3-Year EPS without NRI Growth Rate | 3.8 | |||||
| 3-Year FCF Growth Rate | -34 | |||||
| 3-Year Book Growth Rate | 7.6 | |||||
| Future 3-5Y Total Revenue Growth Rate | -7.51 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 54.67 | |||||
| 9-Day RSI | 51.13 | |||||
| 14-Day RSI | 49.51 | |||||
| 6-1 Month Momentum % | 109.61 | |||||
| 12-1 Month Momentum % | 233.07 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.56 | |||||
| Quick Ratio | 4.56 | |||||
| Cash Ratio | 3.04 | |||||
| Days Sales Outstanding | 45.52 | |||||
| Days Payable | 305.65 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.6 | |||||
| Shareholder Yield % | -2.84 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 59.36 | |||||
| Operating Margin % | -196.58 | |||||
| Net Margin % | -171.78 | |||||
| FCF Margin % | -156.85 | |||||
| ROE % | -247.96 | |||||
| ROA % | -44.79 | |||||
| ROIC % | -168.77 | |||||
| ROC (Joel Greenblatt) % | -2426.35 | |||||
| ROCE % | -62.49 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 28.01 | |||||
| PB Ratio | 45.29 | |||||
| Price-to-Tangible-Book | 82.19 | |||||
| EV-to-EBIT | -15.75 | |||||
| EV-to-EBITDA | -15.92 | |||||
| EV-to-Forward-EBITDA | -17.36 | |||||
| EV-to-Revenue | 30.38 | |||||
| EV-to-Forward-Revenue | 29.94 | |||||
| EV-to-FCF | -21.33 | |||||
| Price-to-Net-Current-Asset-Value | 158.5 | |||||
| Earnings Yield (Greenblatt) % | -6.35 | |||||
| FCF Yield % | -4.76 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Silence Therapeutics PLC Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 31.418 | ||
| EPS (TTM) ($) | -1.46 | ||
| Beta | 1.35 | ||
| Volatility % | 116.76 | ||
| 14-Day RSI | 49.51 | ||
| 14-Day ATR ($) | 1.06977 | ||
| 20-Day SMA ($) | 21.78325 | ||
| 12-1 Month Momentum % | 233.07 | ||
| 52-Week Range ($) | 4.84 - 27.72 | ||
| Shares Outstanding (Mil) | 46.62 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Silence Therapeutics PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Silence Therapeutics PLC Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Silence Therapeutics PLC Frequently Asked Questions
What is Silence Therapeutics PLC(SLN)'s stock price today?
The current price of SLN is $22.29. The 52 week high of SLN is $27.72 and 52 week low is $4.84.
When is next earnings date of Silence Therapeutics PLC(SLN)?
The next earnings date of Silence Therapeutics PLC(SLN) is 2024-05-16 Est..
Does Silence Therapeutics PLC(SLN) pay dividends? If so, how much?
Silence Therapeutics PLC(SLN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers